Accelerating AAV-Based Gene Therapy Development with MS
Human embryonic kidney (HEK) 293 cells and Spodoptera frugiperda (Sf9) insect cells are commonly used to produce adeno-associated virus (AAV)-based gene therapeutics. However, they are likely to exhibit differences in post translational modifications (PTM) depending on the AAV capsid protein serotype which can impact safety and potency.
Here we explore differences shown in AAV serotype 8 produced in Sf9/baculovirus vs HEK293 cells. Using liquid chromatography mass spectrometry (LC-MS), the relative degrees of modification between proteins from the two expression systems were determined and their purity confirmed. Digestion followed by peptide mapping analysis then identified the exact sites and relative abundances of modified amino acids on the capsid proteins.
By attending this webinar, you will learn:
-Why MS is valuable for AAV analysis
-What differences there are in the AAV produced in Sf9 vs HEK293 cells
-How MS can characterize these differences
-Where and how this information can be useful
Presenter: att Stone, PhD (Biologics Workflow Specialist SCIEX)
Presenter: Heather Mallory (Investigator GeneLeap Biotech (Luye Life Science))
